Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling

We introduce the general concept and background knowledge of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling. Examples of application of PBPK/PD modeling are provided. We illustrate the utility of PBPK/PD modeling, particularly in the pharmaceutical drug development process. We project future development on “second-generation” PBPK/PD modeling and In silico toxicology. An emphasis is given to introducing the concepts of PBPK/PD modeling rather than the details of its techniques and processes. Keywords: pharmacokinetic/pharmacodynamic (PBPK/PD) modeling; classical pharmacokinetics; differences; myths; data requirements; chemical interactions; application; validation; second-generation PBPK/PD model; reaction network modeling

[1]  M. Andersen,et al.  Biological regulation of receptor-hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  H. Mehendale,et al.  Potentiation of the hepatotoxicity of carbon tetrachloride following preexposure to chlordecone (kepone) in the male rat. , 1979, Toxicology and applied pharmacology.

[3]  J. Doyle,et al.  Reverse Engineering of Biological Complexity , 2002, Science.

[4]  Harihara M. Mehendale,et al.  13 – Mechanism of the Interactive Amplification of Halomethane Hepatotoxicity and Lethality by Other Chemicals , 1994 .

[5]  Paul S Price,et al.  Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.

[6]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[7]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  H. Mehendale.  Potentiation of halomethane hepatotoxicity: chlordecone and carbon tetrachloride. , 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[9]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[10]  R. S. Thomas,et al.  A physiologically based pharmacodynamic analysis of hepatic foci within a medium-term liver bioassay using pentachlorobenzene as a promoter and diethylnitrosamine as an initiator. , 2000, Toxicology and applied pharmacology.

[11]  W. Dekant,et al.  A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  John C Lipscomb,et al.  Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment , 2001, Toxicology and industrial health.

[13]  Raymond S. H. Yang,et al.  Application of biologically based computer modeling to simple or complex mixtures. , 2002, Environmental health perspectives.

[14]  D. Butler.  Computing 2010: from black holes to biology , 1999, Nature.

[15]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[16]  Robert L. Dedrick,et al.  Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[17]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[18]  M L Gargas,et al.  Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. , 1993, Toxicology and applied pharmacology.

[19]  J. Hasty,et al.  Synchronizing genetic relaxation oscillators by intercell signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Hood,et al.  A Genomic Regulatory Network for Development , 2002, Science.

[21]  Melvin E. Andersen,et al.  Physiologically Based Pharmacokinetic Modeling : Science and Applications , 2005 .

[22]  J. Ferrell.  Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. , 2002, Current opinion in cell biology.

[23]  S H Moolgavkar,et al.  Two-event model for carcinogenesis: biological, mathematical, and statistical considerations. , 1990, Risk analysis : an official publication of the Society for Risk Analysis.

[24]  Raymond S. H. Yang,et al.  A reaction network model for CYP2E1-mediated metabolism of toxicant mixtures. , 2004, Environmental toxicology and pharmacology.

[25]  Y. Sugiyama,et al.  Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4 , 2000, Pharmaceutical Research.

[26]  J. Ward,et al.  Alterations in populations of GST-p-immunoreactive single hepatocytes and hepatocellular foci after a single injection of N-nitrosodiethylamine with or without phenobarbital promotion in male F344/NCr rats. , 1993, Cancer letters.

[27]  Raymond S. H. Yang,et al.  Chemical mixture toxicology: from descriptive to mechanistic, and going on to in silico toxicology. , 2004, Environmental toxicology and pharmacology.

[28]  H J Clewell,et al.  A physiologically based simulation approach for determining metabolic constants from gas uptake data. , 1986, Toxicology and applied pharmacology.

[29]  M. Tatematsu,et al.  Medium-Term Bioassay System for Detection of Carcinogens and Modifiers of Hepatocarcinogenesis Utilizing the GST-P Positive Liver Cell Focus as an Endpoint Marker∗ , 1989, Toxicologic pathology.

[30]  J. Fisher,et al.  Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[31]  H. Bolt,et al.  Pharmacokinetics of halogenated ethylenes in rats , 1978, Archives of Toxicology.

[32]  S. Moolgavkar,et al.  Two-event models for carcinogenesis: incidence curves for childhood and adult tumors☆ , 1979 .

[33]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[34]  Raymond S. H. Yang.  1 – Introduction to the Toxicology of Chemical Mixtures , 1994 .

[35]  M. Tatematsu,et al.  Correlation between medium-term liver bioassay system data and results of long-term testing in rats. , 1990, Carcinogenesis.

[36]  Raymond S. H. Yang,et al.  Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[37]  J W Fisher,et al.  In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. , 1998, Toxicology and applied pharmacology.

[38]  Kathy Chen,et al.  Network dynamics and cell physiology , 2001, Nature Reviews Molecular Cell Biology.

[39]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[40]  M. Elowitz,et al.  Combinatorial Synthesis of Genetic Networks , 2002, Science.

[41]  Jeff Hasty,et al.  Engineered gene circuits , 2002, Nature.

[42]  H. Mehendale.  Role of hepatocellular regeneration and hepatolobular healing in the final outcome of liver injury. A two-stage model of toxicity. , 1991, Biochemical pharmacology.

[43]  E. Davidson,et al.  Modeling transcriptional regulatory networks. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[44]  Melvin E. Andersen,et al.  Physiologically based pharmacokinetic/pharmacodynamic modeling of the toxicologic interaction between carbon tetrachloride and Kepone , 1996, Archives of Toxicology.

[45]  J W Fisher,et al.  A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. , 1998, Toxicology and applied pharmacology.

[46]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[47]  R H Reitz,et al.  Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations. , 1988, Toxicology and applied pharmacology.

[48]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[49]  K. Imaida,et al.  Rapid bioassay methods for carcinogens and modifiers of hepatocarcinogenesis. , 1989, Critical reviews in toxicology.

[50]  Raymond S H Yang,et al.  BioMOL: a computer-assisted biological modeling tool for complex chemical mixtures and biological processes at the molecular level. , 2002, Environmental health perspectives.

[51]  J. Bruckner,et al.  Use of the vial equilibration technique for determination of metabolic rate constants for dichloromethane. , 1996, Toxicology and applied pharmacology.